Global equities dip at end of best month since '09
NEW YORK (Reuters) – World equity benchmarks dipped on Thursday to close their best month in 11 years as a rebound in oil prices, encouraging early results from a COVID-19 treatment trial and expectations of more government stimulus helped ease the pain of February and March.
Safe-haven assets including the dollar and government bonds were little changed, reflecting an unsettled market weighed down by concerns about containing the coronavirus outbreak and jobs data in the United States that was worse than expected.
“It’s a hope-based rally rather than an evidence-based rally,” said Anthony Doyle, cross-asset specialist at fund manager Fidelity International in Sydney.
There were still worries about a second wave of infections, Doyle said, adding that huge piles of cash waiting to go back into the markets suggest investors remained nervous.
MSCI’s gauge of stocks across the globe .MIWD00000PUS shed 0.79% following broad losses in Europe and gains in Asia that pushed Japan’s Nikkei .N225 to a seven-week high.
The index gained 10.5% in April, its best month since an 11.3% gain in April 2009 as the markets were recovering from the 2008 financial crisis.
On Wall Street, the Dow Jones Industrial Average .DJI fell 288.14 points, or 1.17%, to 24,345.72, the S&P 500 .SPX lost 27.08 points, or 0.92%, to 2,912.43 and the Nasdaq Composite .IXIC dropped 25.16 points, or 0.28%, to 8,889.55.
“We have gone back to a turbocharged version of the great financial crisis,” said Simon Fennell, a portfolio manager in William Blair’s global equity team, referring to how markets have surged on mass central bank and government stimulus.
Declines in the equity market came on the heels of a strong finish on Wall Street on Wednesday after partial results from a trial of Gilead’s (GILD.O) antiviral drug remdesivir suggested it could help speed recovery from COVID-19, the respiratory disease caused by the new coronavirus.
Partial results from the 1,063-patient U.S. government trial of Gilead’s remdesivir were hailed as “highly significant” by the top U.S. infectious disease official, Anthony Fauci.
But since treatment hopes do not seem to take into account regulatory and distribution difficulties, should a treatment be found, currency and bond markets were more circumspect.
“Any positive medical development is helpful,” said Westpac FX analyst Sean Callow. “But no one should be counting on a major breakthrough. The key for markets is control of the spread of the virus.”
Safe haven assets held steady after U.S. unemployment claims were greater than expected. Benchmark 10-year notes US10YT=RR last fell 4/32 in price to yield 0.6377%, from 0.627% late on Wednesday.
Initial claims for state unemployment benefits totaled a seasonally adjusted 3.839 million for the week ended April 25, the U.S. government said. That was down from 4.442 million in the prior week.
Commodities were also set to close the month significantly higher. Gold is set for its best month in four years and copper, which is seen as a something of a bellwether of global industry, was on track for its best performance since December 2017.
Hope that demand could soon return helped push oil prices broadly higher. U.S. crude CLc1 recently rose 24.97% to $18.82 per barrel and Brent was at $25.39, up 12.64% on the day.
Source: Read Full Article